课题基金 / 基金详情

Developmental Basis of Aneurysm in Marfan Syndrome and Therapeutic Implication

Developmental Basis of Aneurysm in Marfan Syndrome and Therapeutic Implication
马凡氏综合征动脉瘤的发生基础及治疗意义
批准号:
8379269
负责人:
Harry C., III Dietz
金额:
$48.31万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
未结题
起止时间:
2004-07-01 至

项目摘要

项目成果

Harry C., III Dietz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Marfan syndrome (MFS) is a common disorder caused by mutations in the gene encoding the matrix protein fibrillin-1. Our prior work has shown that many manifestations of MFS, including aortic aneurysm, valve disease, emphysema and skeletal muscle myopathy, are caused by excessive activation of and signaling by the TGFbeta family of growth factors and can be attenuated by TGFbeta blockade in mouse models. The prevailing view has been that MFS manifests abnormal behaviors of "normal" cells due to alterafions in their extracellular environment. We now present evidence for "abnormal" cells within the aortic wall of adult MFS mice that have undergone a TGFbeta-dependent permanent transifion in identity and character during early development due to a process termed endothelial-to-mesenchymal transifion (EnMT). After transifion, resulfing myofibroblasts exhibit many deleterious behaviors including high TGFbeta signaling, angiotensin II (Angll)-dependent fibrosis, and high expression of matrix-degrading enzymes. The major hypotheses to be tested in this work are that EnMT-derived cells drive progression of disease and that EnMT continues to populate the ascending aorta during postnatal life in disease states. Using mouse models, we will determine the pathways that drive EnMT in the aorta of fibrillin-1 deficient mice and will purify EnMT-derived cells, allowing identification of their deleterious behaviors and explorafion of strategies to tame them. Currently, we can envision at least 9 different therapeutic agents that will theoretically prevent ongoing EnMT and/or modulate the nonproducfive performance of myofibroblasts resident within the aortic wall at the time of initiation of treatment. These will be tested in genetically defined and validated mouse models of MFS. Remarkably, a number of these agents are already in clinical use for other indications, suggesting the potential for rapid translafion to people with MFS. Our current data suggest a developmentally-imposed fixed alterafion in cellular idenfity in the prediposition for apparently acquired late-onset phenotypes in MFS, This paradigm represents a novel way of thinking about genefic predisposifion, aids in the elucidation of therapeufic limitafions and opportunities, and will likely prove relevant to other condifions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanistic and Therapeutic Investigations of Scleroderma
  • 批准号:
    9304862
  • 项目类别:
  • 资助金额:
    $35.97万
  • 财政年份:
    2016
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
Systems Biology and Connective Tissue Disorders
  • 批准号:
    8063338
  • 项目类别:
  • 资助金额:
    $4.0万
  • 财政年份:
    2010
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection
  • 批准号:
    7935405
  • 项目类别:
  • 资助金额:
    $49.82万
  • 财政年份:
    2009
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection
  • 批准号:
    7815944
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2009
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
海外基金